VITAE Biomedical entered the National Biotechnology Research Park in 2020, and then accelerated the pace of research and development, successfully developed the prototype of the Lung Cancer urine IVD Reagent, and initiated clinical trials in early 2021.

In order to promote the popularization of lung cancer screening and make it more convenient for use, VITAE Biomedical has also developed a Urine Collection and transport Device suitable for home use, and successfully obtained the certification of the medical material class-1 by MOHW in September 2021. The first Lung Cancer urine IVD Reagent also successfully obtained the international CE certification by EU in November of the same year. At the end of 2021, VITAE Biomedical further won the 18th National Innovation Award.

This year, VITAE Biomedical will debut at Bio Asia-Taiwan 2022 to present great achievements of R&D results, and take this international event to enter the global market and keep moving forward.

Source URL：https://expo.bioasiataiwan.com/en/visitorExNewsDetail.asp?id=9963
Media：BIO Asia-Taiwan Website